Article Information
vol. 8 no. 4
PubMed
Published By
Online ISSN
History
- Received May 16, 2022
- Accepted June 10, 2022
- Published online October 24, 2022.
Article Versions
- previous version (August 4, 2022 - 06:00).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright ©The authors 2022. This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Author Information
- Toby M. Maher1,2⇑,
- Christina Schlecker3,
- Doreen Luedtke4,
- Sebastian Bossert4,
- Donald F. Zoz5 and
- Armin Schultz6
- 1Inflammation, Repair, and Development Section, National Heart and Lung Institute, Imperial College London, London, UK
- 2Keck Medicine of USC, Los Angeles, CA, USA
- 3Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany
- 4Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
- 5Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USA
- 6CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
- Corresponding author: Toby Maher (Toby.Maher{at}med.usc.edu)
Funding
Boehringer Ingelheim
N/A
Article usage
Altmetrics
Vol 8 Issue 4
Table of Contents
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
